

Neil J Shah

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/360145/publications.pdf>

Version: 2024-02-01

15
papers

252
citations

1684188

5
h-index

1281871

11
g-index

15
all docs

15
docs citations

15
times ranked

401
citing authors

#	ARTICLE	IF	CITATIONS
1	Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Nonâ€Clear-Cell Renal Cell Carcinoma and Genomic Correlates. <i>Journal of Clinical Oncology</i> , 2022, 40, 2333-2341.	1.6	72
2	The Impact of Androgen Deprivation Therapy on COVID-19 Illness in Men With Prostate Cancer. <i>JNCI Cancer Spectrum</i> , 2022, 6, .	2.9	6
3	Contribution of the Skinâ€Gut Axis to Immune-Related Adverse Events with Multi-System Involvement. <i>Cancers</i> , 2022, 14, 2995.	3.7	5
4	Matched Molecular Profiling of Cell-Free DNA and Tumor Tissue in Patients With Advanced Clear Cell Renal Cell Carcinoma. <i>JCO Precision Oncology</i> , 2022, , .	3.0	3
5	The Risk of Opportunistic Infections and the Role of Antibiotic Prophylaxis in Patients on Checkpoint Inhibitors Requiring Steroids. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 800-807.e1.	4.9	5
6	Germline Variants Identified in Patients with Early-onset Renal Cell Carcinoma Referred for Germline Genetic Testing. <i>European Urology Oncology</i> , 2021, 4, 993-1000.	5.4	16
7	Association between Body Mass Index and Immune-Related Adverse Events (irAEs) among Advanced-Stage Cancer Patients Receiving Immune Checkpoint Inhibitors: A Pan-Cancer Analysis. <i>Cancers</i> , 2021, 13, 6109.	3.7	9
8	A case of checkpoint inhibitor-induced celiac disease. , 2019, 7, 203.		25
9	Safety and efficacy of immune checkpoint inhibitors (ICIs) in cancer patients with HIV, hepatitis B, or hepatitis C viral infection. , 2019, 7, 353.		91
10	Real-world outcomes of underrepresented patient populations treated with immune checkpoint inhibitors (ICIs): African American descent, poor ECOG performance status, and chronic viral infections.. <i>Journal of Clinical Oncology</i> , 2019, 37, 2587-2587.	1.6	5
11	Combined Targeting of Bcl-2 and XPO1 Overcomes Acquired Resistance to Tyrosine Kinase Inhibitors in the FLT3-ITD/TKD Double Mutant AML. <i>Blood</i> , 2018, 132, 2640-2640.	1.4	1
12	Delayed toxicities with anti-PD-1 and anti-PDL-1 immune checkpoint inhibitors (ICIs).. <i>Journal of Clinical Oncology</i> , 2018, 36, e15074-e15074.	1.6	9
13	Molecular Epidemiologic Associations in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) within the United States. <i>Blood</i> , 2018, 132, 1393-1393.	1.4	0
14	Clinical presentation of immune-related colitis associated with PD-1 inhibitor monotherapy (MONO) and combination PD-1/CTLA-4 inhibitors (COMBO) in melanoma.. <i>Journal of Clinical Oncology</i> , 2017, 35, 9566-9566.	1.6	5
15	Successful Renal Transplant Tolerance Following a Haplo-Identical Allogeneic Hematopoietic Stem Cell Transplant - a Case Report and Review of Literature. <i>Blood</i> , 2016, 128, 5879-5879.	1.4	0